Is Jaguar Health, Inc. (JAGX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 551.4% / 30% | 120.8% / 30% | 24.9% / 30% | 70.06% / 5% | ✗ NOT HALAL |
| DJIM | 551.4% / 33% | 120.8% / 33% | 24.9% / 33% | 70.06% / 5% | ✗ NOT HALAL |
| MSCI | 68.4% / 33% | 15.0% / 33% | 3.1% / 33% | 70.06% / 5% | ✗ NOT HALAL |
| S&P | 551.4% / 33% | 120.8% / 33% | 24.9% / 33% | 70.06% / 5% | ✗ NOT HALAL |
| FTSE | 68.4% / 33% | 15.0% / 33% | 3.1% / 50% | 70.06% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 81.9% | |
| Operating Margin | -234.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -411.6% | |
| Return on Assets (ROA) | -38.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$29M |
| Free Cash Flow | -$30M |
| Total Debt | $37M |
| Debt-to-Equity | 731.8 |
| Current Ratio | 0.8 |
| Total Assets | $53M |
Price & Trading
| Last Close | $0.39 |
| 50-Day MA | $0.63 |
| 200-Day MA | $1.60 |
| Avg Volume | 4.0M |
| Beta | 0.0 |
|
52-Week Range
$0.34
| |
About Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Jaguar Health, Inc. (JAGX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Jaguar Health, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Jaguar Health, Inc.'s debt ratio?
Jaguar Health, Inc.'s debt ratio is 551.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 68.4%.
What are Jaguar Health, Inc.'s key financial metrics?
Jaguar Health, Inc. has a market capitalization of $4M, and revenue of $12M. Return on equity stands at -411.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.